In this study, we demonstrated that pre-treatment radiologically defined sarcopenia (low SMI) was strongly associated with reduced pathological complete response rates in patients with HER2-positive and triple-negative breast cancer receiving neoadjuvant therapy. This evidence concerns the gene ERBB2 and sarcopenia.